VHsquared (United Kingdom)

Preclinical Development of a Novel, Orally-Administered Anti-Tumour Necrosis Factor Domain Antibody for the Treatment of Inflammatory Bowel Disease

Jenny Crowe, Kevin J. Roberts, Timothy M. Carlton et al. · Scientific Reports · 2018 · 56 citations · Full text

Oral delivery of the anti-tumor necrosis factor α domain antibody, V565, results in high intestinal and fecal concentrations with minimal systemic exposure in cynomolgus monkeys

Jenny Crowe, Kevin J. Roberts, Timothy M. Carlton et al. · Drug Development and Industrial Pharmacy · 2018 · 41 citations · Full text

Oral Anti-Tumour Necrosis Factor Domain Antibody V565 Provides High Intestinal Concentrations, and Reduces Markers of Inflammation in Ulcerative Colitis Patients

Suhail Nurbhai, Kevin J. Roberts, Timothy M. Carlton et al. · Scientific Reports · 2019 · 37 citations · Full text

Preclinical development of a bispecific TNFα/IL-23 neutralising domain antibody as a novel oral treatment for inflammatory bowel disease

Kevin J. Roberts, Marion F. Cubitt, Timothy M. Carlton et al. · Scientific Reports · 2021 · 30 citations · Full text

A Phase 2b Dose-Ranging Efficacy and Safety Study of Tralokinumab in Adult Patients with Moderate to Severe Atopic Dermatitis

Andreas Wollenberg, Michael Howell, Emma Guttman‐Yassky et al. · SKIN The Journal of Cutaneous Medicine · 2018 · 18 citations · Full text

Atopic Dermatitis, Phase 2B, Cutaneous Biology +14